Loading...
Please wait, while we are loading the content...
Similar Documents
Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction
| Content Provider | Semantic Scholar |
|---|---|
| Author | Niu, Jinghui Chen, Tao Yin, Hongshan Wang, Tao Jiang, Z. |
| Copyright Year | 2018 |
| Abstract | BACKGROUND This study aimed to investigate intracoronary nicorandil treatment on the no-reflow phenomenon (NRP) during primary percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) and to compare nicorandil with sodium nitroprusside. MATERIAL AND METHODS Patients with sustained acute STEMI who underwent primary PCI (N=120) were randomly assigned to three groups: the nicorandil-treated group (N=40) had 2 mg of nicorandil injected into the coronary artery at 2 mm beyond the occlusion with balloon pre-dilation; the sodium nitroprusside-treated group (N=40) underwent the same procedure, but with 200 μg of sodium nitroprusside; the control group (N=40) received PCI and balloon pre-dilation only. Coronary angiography, incidence of NRP, hypotensive episodes, ST-segment resolution (STR) rate, levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase-MB (CK-MB), cardiac troponin I (cTnI), wall motion score index (WMSI), and left ventricular ejection fraction (LVEF) were measured before and after primary PCI. Major adverse cardiovascular events (MACEs) post-PCI and at three-month follow-up were recorded. RESULTS Patients in the sodium nitroprusside and nicorandil groups had significantly improved thrombolysis in myocardial infarction (TIMI) scores, TIMI myocardial perfusion grade (TMPG), and ST-segment elevation resolution (STR) (P<0.05), and a significantly lower incidence of NRP (P=0.013). The incidence of intraoperative hypotension in the sodium nitroprusside group was significantly greater than the nicorandil and control groups (P=0.035). CONCLUSIONS Patients with sustained acute STEMI undergoing primary PCI, treated with intracoronary nicorandil had a reduced incidence of the NRP, improved myocardial perfusion and cardiac function. |
| Starting Page | 2767 |
| Ending Page | 2776 |
| Page Count | 10 |
| File Format | PDF HTM / HTML |
| PubMed reference number | 29726480v1 |
| Alternate Webpage(s) | https://doi.org/10.12659/MSM.906815 |
| DOI | 10.12659/msm.906815 |
| Journal | Medical science monitor : international medical journal of experimental and clinical research |
| Volume Number | 24 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Addison Disease Amino-terminal pro-brain natriuretic peptide Artificial cardiac pacemaker Cardiac troponin I Cardiomyopathies Coronary Arteriosclerosis Coronary angiography Creatine Kinase MB Isoenzyme Ejection fraction (procedure) Left ventricular ejection fraction Nesiritide Nicorandil Nitroprusside Pathological Dilatation Patients Percutaneous Coronary Intervention PersonNameUse - assigned Plant Physiological Phenomena ProB-Type Natriuretic Peptide Measurement Raynaud Phenomenon ST segment elevation myocardial infarction Shy-Drager Syndrome Thrombolysis, function angiogram |
| Content Type | Text |
| Resource Type | Article |
